Search Results - "MATINING, Roy M"

Efficacy of a nucleoside-sparing regimen of darunavir/ ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262) by TAIWO, Babafemi, LU ZHENG, ERON, Joseph J, GALLIEN, Sebastien, MATINING, Roy M, KURITZKES, Daniel R, WILSON, Cara C, BERZINS, Baiba I, ACOSTA, Edward P, BASTOW, Barbara, KIM, Peter S

“…To explore darunavir/ritonavir (DRV/r) plus raltegravir (RAL) combination therapy in antiretroviral-naive patients. Phase IIb, single-arm, open-label,…”
Get full text

Older age is associated with peripheral blood expansion of naïve B cells in HIV-infected subjects on antiretroviral therapy by Van Epps, Puja, Matining, Roy M, Tassiopoulos, Katherine, Anthony, Donald D, Landay, Alan, Kalayjian, Robert C, Canaday, David H

“…Older HIV infected subjects were previously found to have significant B cell expansion during initial antiretroviral therapy in a prospective…”
Get full text

Wilms' tumor 1 (WT1) antigen is overexpressed in Kaposi Sarcoma and is regulated by KSHV vFLIP by Morales, Ayana E, Gumenick, Ruby, Genovese, Caitlyn M, Jang, Yun Yeong, Ouedraogo, Ariene, Ibáñez de Garayo, Maite, Pannellini, Tania, Patel, Sanjay, Bott, Matthew E, Alvarez, Julio, Mun, Sung Soo, Totonchy, Jennifer, Gautam, Archana, Delgado de la Mora, Jesus, Chang, Stephanie, Wirth, Dagmar, Horenstein, Marcelo, Dao, Tao, Scheinberg, David A, Rubinstein, Paul G, Semeere, Aggrey, Martin, Jeffrey, Godfrey, Catherine C, Moser, Carlee B, Matining, Roy M, Campbell, Thomas B, Borok, Margaret Z, Krown, Susan E, Cesarman, Ethel

“…In people living with HIV, Kaposi Sarcoma (KS), a vascular neoplasm caused by KS herpesvirus (KSHV/HHV-8), remains one of the most common malignancies…”
Get full text

Adverse Impact of HIV-1 on Long-term Outcomes Following HCV DAA Treatment: Final Results of ACTG A5320, the Viral Hepatitis C Infection Long-term Cohort Study (VHICS) by Wyles, David L, Kang, Minhee, Matining, Roy M, Murphy, Robert L, Peters, Marion G

“…Abstract Background Long-term outcome data after hepatitis C virus (HCV) treatment are limited, particularly for comparisons between persons with and without…”
Get full text

The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1 by Jacobson, Jeffrey M, Bosinger, Steven E, Kang, Minhee, Belaunzaran-Zamudio, Pablo, Matining, Roy M, Wilson, Cara C, Flexner, Charles, Clagett, Brian, Plants, Jill, Read, Sarah, Purdue, Lynette, Myers, Laurie, Boone, Linda, Tebas, Pablo, Kumar, Princy, Clifford, David, Douek, Daniel, Silvestri, Guido, Landay, Alan L, Lederman, Michael M

“…Immune activation associated with HIV-1 infection contributes to morbidity and mortality. We studied whether chloroquine, through Toll-like receptor (TLR)…”
Get more information

Safety, Tolerability, and Immunogenicity of Repeated Doses of DermaVir, a Candidate Therapeutic HIV Vaccine, in HIV-Infected Patients Receiving Combination Antiretroviral Therapy: Results of the ACTG 5176 Trial by Rodriguez, Benigno, Asmuth, David M, Matining, Roy M, Spritzler, John, Jacobson, Jeffrey M, Mailliard, Robbie B, Li, Xiao-Dong, Martinez, Ana I, Tenorio, Allan R, Lori, Franco, Lisziewicz, Julianna, Yesmin, Suria, Rinaldo, Charles R, Pollard, Richard B

“…BACKGROUND:HIV-specific cellular immune responses are associated with control of viremia and delayed disease progression. An effective therapeutic vaccine…”
Get full text

Continued Low Rates of Hepatitis C Virus (HCV) Recurrence in HCV/HIV- and HCV-Infected Participants Who Achieved Sustained Virologic Response After Direct-Acting Antiviral Treatment: Final Results From the AIDS Clinical Trials Group A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS) by Wyles, David L, Kang, Minhee, Matining, Roy M, Murphy, Robert L, Peters, Marion G

“…Abstract Final results from the long-term Viral Hepatitis C Infection Long-term Cohort Study (V-HICS) found low rates of hepatitis C virus (HCV) recurrence…”
Get full text

The Safety and Immunogenicity of an Interleukin-12–Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection by Jacobson, Jeffrey M, Zheng, Lu, Wilson, Cara C, Tebas, Pablo, Matining, Roy M, Egan, Michael A, Eldridge, John, Landay, Alan L, Clifford, David B, Luetkemeyer, Anne F, Tiu, Jennifer, Martinez, Ana L, Janik, Jennifer, Spitz, Teresa A, Hural, John, McElrath, Juliana, Frahm, Nicole

“…BACKGROUND:Therapeutic vaccination is being studied in eradication and “functional cure” strategies for HIV-1. The Profectus Biosciences multiantigen (MAG)…”
Get full text

Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS) by Wyles, David L, Kang, Minhee, Matining, Roy M, Murphy, Robert L, Peters, Marion G

“…Abstract Hepatitis C virus (HCV) recurrence rates were similar between those with HCV/HIV co-infection (0.35/100 person-years) and HCV infection (0.42/100…”
Get full text

Older HIV-infected patients on antiretroviral therapy have B-cell expansion and attenuated CD4 cell increases with immune activation reduction by KALAYJIAN, Robert C, SPRITZLER, John, MATINING, Roy M, FISCUS, Susan A, GROSS, Barry H, FRANCIS, Isaac R, POLLARD, Richard B, LEDERMAN, Michael M, LANDAY, Alan

“…The contribution of immune activation to accelerated HIV-disease progression in older individuals has not been delineated. Prospective multicenter cohort of…”
Get full text

Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy by Taiwo, Babafemi, Matining, Roy M, Zheng, Lu, Lederman, Michael M, Rinaldo, Charles R, Kim, Peter S, Berzins, Baiba I, Kuritzkes, Daniel R, Jennings, Amy, Eron, Jr, Joseph J, Wilson, Cara C

“…One of the goals of antiretroviral therapy (ART) is to attenuate HIV-induced systemic immune activation and inflammation. We determined the dynamics of…”
Get full text

Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial by Krown, Susan E, Moser, Carlee B, MacPhail, Patrick, Matining, Roy M, Godfrey, Catherine, Caruso, Stephanie R, Hosseinipour, Mina C, Samaneka, Wadzanai, Nyirenda, Mulinda, Busakhala, Naftali W, Okuku, Fred M, Kosgei, Josphat, Hoagland, Brenda, Mwelase, Noluthando, Oliver, Vincent O, Burger, Henriette, Mngqibisa, Rosie, Nokta, Mostafa, Campbell, Thomas B, Borok, Margaret Z, Moses, Agnes, Kanyama, Cecilia, Mukwekwerere, Pamela, Gudza, Ivy, Chauwa, Felluna, Ulaya, Godwin, Kutto, Irene, Cheruiyot, Priscilla, Okello, Clement, Nakaganda, Annet, Koskei, Geoffrey, Keter, Winnie, Netto, Juliana, Baião, Tamiris, Govender, Iveshni, O'Connell-Maritz, Jessica, Cain, Kevin, Okanda, John, Cornelissen, Lynne, Van Schalkwyk, Marije, Sikhosana, Rejoice, Ngcobo, Minenhle, Lee, Jeannette Y., Harrison, Taylor, Wachsman, William, Shin, Katherine, Evans, Scott, Rothenberg, Jennifer, Hosey, Lara, McCarthy, Sean, Martinez-Maza, Otoniel, Rinaldo, Charles, Dittmer, Dirk, Fletcher, Courtney, Rudek, Michelle, Asmelash, Aida, Hughes, Valery, Schouten, Jeffrey, Shugarts, David, Kujinga, Tapiwanashe, Zadzilka, Amanda, Kerui, Fredrick, Robertson, Debora, Rooney, James, Sewal, Krishna, Gottshall, Brian

“…Optimal treatment regimens for AIDS-associated Kaposi sarcoma, a frequent contributor to morbidity and mortality among people with HIV, have not been…”
Get full text

Wilms' tumor 1 by Morales, Ayana E, Gumenick, Ruby, Genovese, Caitlyn M, Jang, Yun Yeong, Ouedraogo, Ariene, Ibáñez de Garayo, Maite, Pannellini, Tania, Patel, Sanjay, Bott, Matthew E, Alvarez, Julio, Mun, Sung Soo, Totonchy, Jennifer, Gautam, Archana, Delgado de la Mora, Jesus, Chang, Stephanie, Wirth, Dagmar, Horenstein, Marcelo, Dao, Tao, Scheinberg, David A, Rubinstein, Paul G, Semeere, Aggrey, Martin, Jeffrey, Godfrey, Catherine C, Moser, Carlee B, Matining, Roy M, Campbell, Thomas B, Borok, Margaret Z, Krown, Susan E, Cesarman, Ethel

Get full text

Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy by Li, Jonathan Z, Chapman, Brad, Charlebois, Patrick, Hofmann, Oliver, Weiner, Brian, Porter, Alyssa J, Samuel, Reshmi, Vardhanabhuti, Saran, Zheng, Lu, Eron, Joseph, Taiwo, Babafemi, Zody, Michael C, Henn, Matthew R, Kuritzkes, Daniel R, Hide, Winston, Wilson, Cara C, Berzins, Baiba I, Acosta, Edward P, Bastow, Barbara, Kim, Peter S, Read, Sarah W, Janik, Jennifer, Meres, Debra S, Lederman, Michael M, Mong-Kryspin, Lori, Shaw, Karl E, Zimmerman, Louis G, Leavitt, Randi, De La Rosa, Guy, Jennings, Amy

“…The impact of raltegravir-resistant HIV-1 minority variants (MVs) on raltegravir treatment failure is unknown. Illumina sequencing offers greater throughput…”
Get full text

Older Age Is Associated with Peripheral Blood Expansion of Naive B Cells in HIV-Infected Subjects on Antiretroviral Therapy: e107064 by Epps, Puja Van, Matining, Roy M, Tassiopoulos, Katherine, Anthony, Donald D, Landay, Alan, Kalayjian, Robert C, Canaday, David H

“…Older HIV infected subjects were previously found to have significant B cell expansion during initial antiretroviral therapy in a prospective…”
Get full text